Bioyong will pay Biodesix approximately $38 million over the course of the collaboration. The system will be designed for clinical use in China, with potential expansion into other Asia-Pacific countries.

With nearly 850,000 new lung cancer diagnoses predicted in 2020, China represents approximately 37 percent of new cases worldwide.

“We believe that cancer is a global problem,” said David Brunel, CEO of Biodesix. “Patients and their physicians everywhere want cancer treatment that is grounded in precision medicine including therapy selection that reflects the full spectrum of biological information provided by our multivariate, molecular and proteomic assays. By collaborating with Bioyong, we are taking a major step toward making our technology available to a large portion of the world’s lung cancer patients.”

Biodesix is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Bioyong Technology is a developer of mass spectrometry technologies.

A plethora of new treatments for lung cancer are being tested in ongoing clinical trials. While several promising methods of detection and therapy should be available to the public in the next few years. The choice from different treatments available like surgery, chemotherapy, radiation therapy Bronx( http://www.advancedradiationcenters.com/cancers/lung-cancer/ ) and so on will depend on the extent of spread and the health conditions of the patient. There are two types of radiation therapy used to treat lung cancer - external beam radiation therapy, and internal beam radiation therapy (brychytherapy). Both have their benefits for lung cancer patients, but they also have their side-effects too.